Back to Authors

Franciosi, Alessandro N.

0000-0002-4241-8718

Mayo Clinic

University College Dublin

Citations 2

Dipnech: Clinical Characteristics of an International Case Series
O'Brien, H., O’Callaghan, Michael , Penugonda, M., Almeamar, Hussein , Samhouri, Bilal F. , Veltkamp, Marcel , Manali, Effrosyni D. , Lazaratou, A., Papiris, Spiridon, Carr, Laurie, Kolilekas, Lykourgos , Daniil, Z., Hernández‐González, Fernanda , Torres, J. Sellares, O’Shea, Diarmuid , Murphy, D.J., Fabre, Aurélie , Forde, Sarah H. , Diesler, Rémi , Ryu, Jay H. , Bonella, Francesco , Cottin, Vincent , Taillé, Camille , McCormack, Francis X. , Gupta, Nishant , Strosberg, Jonathan , Lococo, Filippo , Harari, Sergio , Bouros, Demosthenes , Dimeas, Ilias E. , Torres, J. Sellares, Spagnolo, Paolo , Franciosi, Alessandro N. , Crowley, Rachel Katherine , O’Toole, Dermot , Byrne, Adam J. , Keane, Michael P. , Fournel, Ludovic , McCarthy, Cormac

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A1804-A1804

10.1164/ajrccm.2025.211.abstracts.a1804 Get It

Abstract Rationale: Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is a pulmonary condition characterised by neuroendocrine cell proliferation along respiratory bronchioles resulting in tumourlet formation which may progress to pulmonary carcinoid. DIPNECH is a rare and under-recognised condition that predominantly affects females, with an estimated worldwide incidence of 5-6 people per million population. Given it's rarity and the poor understanding around the pathogenesis and treatment of this condition, we undertook the largest international case series to date of DIPNECH patients. We aim to further characterise this patient cohort to better understand the clinical features, identify common pulmonary function test (PFT) patterns and radiographic findings and describe current treatment practices. Methods: We collated data from 17 centres across 8 different countries comprising a total of 258 patients. Data collected included patient demographics, smoking history, symptoms, co-morbidities, pathological diagnosis, imaging findings, PFT pattern and therapies. Results: In total 258 patients were identified. The median age was 65 (SD+/- 10.6). 241 (93%) were female. 39% (n= 94/243) were ex-smokers. 79% (n=186/234) of patients reported pulmonary symptoms with cough being the most common symptom reported in 81% (n=151/186) of patients. Many patients were polysymptomatic, with cough and dyspnoea being the most common combination of symptoms described. (50.54%; n=94/186). Complete spirometry pattern was documented for 180 patients (69.78%) with an obstructive pattern being the most commonly observed (n=76/180; 42%). 27.5% (n=41/139) had clinically significant FEV1 reversibility post bronchodilator administration. Pathology specimens were available in 219 cases. Most common pathological features were neuroendocrine hyperplasia which was observed in 75% (n=165/219) and tumourlets in 74% (n=162/219) of cases. Carcinoid, either typical or atypical, was observed in 64% (n=141/219) of samples. 252 patients had computed tomography (CT) imaging performed. Pulmonary nodules were the most common feature identified in 99.60% of cases (248/250). Mosaic attenuation (69.30%; n=50/173) and airway dilatation (28.90%; n=50/173) were also frequently reported. There was no significant correlation between symptoms (cough, dyspnoea, wheeze) and airway dilatation (p=0.496), mosaic attenuation (p=0.496) and PFT pattern (p=0.837). There was a significant association between presence of symptoms and mosaic attenuation on CT (p=0.003). Conclusions: DIPNECH, while a rare disorder, is understudied. This international case series is the largest performed to date and highlights the complexity in management of these patients.